Difference between revisions of "Part:BBa K3142009:Design"
(→Design Notes) |
|||
| Line 7: | Line 7: | ||
===Design Notes=== | ===Design Notes=== | ||
| − | The sequence has been optimized. It is a small molecule bioactive peptide that is difficult to directly biosynthesize. Therefore, the fusion expression strategy is currently used. | + | The sequence has been optimized for lactic acid bacteria. It is a small molecule bioactive peptide that is difficult to directly biosynthesize. Therefore, the fusion expression strategy is currently used. |
| − | + | ||
| − | + | ||
===Source=== | ===Source=== | ||
Revision as of 21:56, 20 October 2019
Artificially designed antihypertensive heptapeptide（FKGKYYP）
Assembly Compatibility:
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
Design Notes
The sequence has been optimized for lactic acid bacteria. It is a small molecule bioactive peptide that is difficult to directly biosynthesize. Therefore, the fusion expression strategy is currently used.
Source
NO